Literature DB >> 25801496

Recent advances in management of diabetic macular edema.

Koushik Tripathy1, Yog Raj Sharma, Karthikeya R, Rohan Chawla, Varun Gogia, Subodh Kumar Singh, Pradeep Venkatesh, Rajpal Vohra.   

Abstract

Diabetic macular edema (DME) is the leading cause of moderate vision loss in diabetics. Modalities to image and monitor DME have evolved much in the last decade. Systemic control is the most important part of management. Available ocular management options include intravitreal antivascular endothelial growth factor (anti-VEGF) agents, laser, steroids (intravitreal or peribulbar), vitrectomy, topical medications and others. Anti-VEGF agents are increasingly being used in clinical practice with good clinical response and are currently the preferred mode of treatment worldwide.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25801496     DOI: 10.2174/1573399811999150324120640

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  8 in total

1.  Encouraging results of 25G+ minimally invasive vitrectomy surgery for diabetic tractional retinal detachment.

Authors:  Koushik Tripathy
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-30       Impact factor: 3.117

Review 2.  Ascorbic acid repletion: A possible therapy for diabetic macular edema?

Authors:  James M May
Journal:  Free Radic Biol Med       Date:  2016-02-17       Impact factor: 7.376

Review 3.  Management of diabetic macular edema in Japan: a review and expert opinion.

Authors:  Hiroko Terasaki; Yuichiro Ogura; Shigehiko Kitano; Taiji Sakamoto; Toshinori Murata; Akito Hirakata; Tatsuro Ishibashi
Journal:  Jpn J Ophthalmol       Date:  2017-12-05       Impact factor: 2.447

4.  Evaluation of rhegmatogenous retinal detachments using Optos ultrawide field fundus fluorescein angiography and comparison with ETDRS 7 field overlay.

Authors:  Koushik Tripathy; Rohan Chawla; Bhushan Ratansingh Wadekar; Pradeep Venkatesh; Yog Raj Sharma
Journal:  J Curr Ophthalmol       Date:  2018-07-03

5.  Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN(®) (Fluocinolone Acetonide).

Authors:  Farhat Butt; Kamron Khan; Saadia Chaudhry; Rehna Khan
Journal:  Ophthalmol Ther       Date:  2016-05-19

6.  Scleral abscess following posterior subtenon triamcinolone acetonide injection for diabetic macular edema.

Authors:  Koushik Tripathy; Yog Raj Sharma; Harsh Inder Singh; Rajpal Vohra; Pradeep Venkatesh; Shabeer Basheer
Journal:  Saudi J Ophthalmol       Date:  2016-01-02

7.  Successful Management of Proliferative Diabetic Retinopathy and Multiple Choroidal Tubercles in a Patient with Miliary Tuberculosis.

Authors:  Rohan Chawla; Pradeep Venkatesh; Koushik Tripathy; Sunil Chaudhary; S K Sharma
Journal:  J Ophthalmic Vis Res       Date:  2018 Apr-Jun

8.  The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen.

Authors:  Yoshihiro Takamura; Teruyo Kida; Hidetaka Noma; Makoto Inoue; Shigeo Yoshida; Taiji Nagaoka; Kousuke Noda; Yutaka Yamada; Masakazu Morioka; Makoto Gozawa; Takehiro Matsumura; Masaru Inatani
Journal:  J Clin Med       Date:  2021-12-08       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.